Description: Clinical Development and Innovation Forum 2021| 临床开发与创新合作论坛2021
clinical development and innovation forum 2021| 临床开发与创新合作论坛2021 (2)
China and Asia over the decades has been playing an increasingly important role in the context of clinical research activities due to the significant scientific investment by multinational companies as well as rapidly booming China domestic R&D programs. In past few years, the China regulatory agency has also issued several regulations and initiatives to accelerate the review and approval and improve the quality of new drugs and medical devices. With the joining of ICH in 2017, the government is continuing
Approx. 7 00 senior R&D, Clinical and Translational, Medical and Regulatory executives and scientists are expected to attend the Clinical Development and Innovation Forum 2023 . The participants will mainly come from the Pharma/Biotech, Academia, Investigational Sites, Regulatory Agencies, CROs, Central Labs, Technology and Service providers with the main responsibilities including: